Clinical outcomes of patients with MRD-positive B-ALL after CD19/CD22 bispecific CAR-T cells.
neurotoxic, CRS
DISEASE
The bar chart shows the clinical response and follow-up of patients during CAR-T therapy. Each bar represents an individual patient and the study number. The different colors represent different disease status.For total patients, the median relapse free survival (RFS) and overall survival (OS) were not reached (Supplemental Fig. For the 11 patients in the first-line consolidation group, the median RFS and OS were not reached (Supplementary Fig. Peripheral blood CAR T-cell expansion was observed in all 15 patients, with a median time to reach the peak CAR-T cell concentration (Cmax) of 10 days (range, 7–14). Cmax and AUCIn the present study, only 26.7% of patients developed CRS without severe CRS and early neurotoxic effects, although a high dose of CD19/22 CAR-T cells of 5 × 10Although the Cmax of CD19/CD22 CAR-T cell expansion was relatively lower, but it still had a good efficacy, which was consistent with the report by Park et al [